Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Bright Minds Biosciences Inc. (DRUG) Market Cap & Valuation Ratios

Bright Minds Biosciences Inc. (DRUG) has a market cap of $237.4M, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · read by EquiReason

DRUGBright Minds Biosciences Inc.Follow DRUG — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
237.4M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
17 Aug, in -68 days

Peers

biotechnology · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
DRUG0.2————+4943%——
FATE0.3—15.3——-23%—-78%
RCKT0.3——————-82%
OCGN0.3—51.3——-4%——
LRMR0.2——————-267%
VNDA0.2—0.9——+6%-86%-65%
PALI0.2———————
LXEO0.2——————-78%
KROS0.2————-94%—-956%
IKT0.2——————-54%
ALEC0.2—3.0——-83%——
Median of these 10—9.1——-23%-86%-78%

.

Growth vs. price

each dot a company · hover or tap for values

Bright Minds Biosciences Inc. — questions

What is Bright Minds Biosciences Inc.'s market cap?
$237.4M.

Every figure on this page comes from Bright Minds Biosciences Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.